Skip to content
Contact Us
iStock-1421515036 (2) iStock-1421515036 (2)

Gene Expression Profiling of Biopsies

Gene expression profiling of tumor biopsies and liquid biopsies can provide insight into inflammation and overall immune status
Profiling of biopsies by gene expression can serve as a tool for screening tumors that may respond to treatments such as checkpoint inhibitors, for evaluating therapeutic efficacy, for illuminating mechanism of action, and for a range of other applications

Comprehensive and quantitative gene expression profiling

Precision offers gene expression profiling and transcriptomics assays to monitor immune status using next generation sequencing (NGS), NanoString, qPCR, and Droplet Digital™ PCR (ddPCR) technologies. For sample types and needs other than immune profiling of biopsies, Precision also offers a full suite of genomics applications.

Our services are designed to meet your project objectives, whether through pre-existing panels or a customized assay.

Illumina and Thermo Fisher NGS Sequencers

We use both Illumina and Thermo Fisher for next-gen sequencing. Also, RNA-seq studies are done using Illumina, including the AmpliSeq for Illumina Immune Response Panel.

NanoString nCounter®

For highly multiplexed, quantitative gene expression studies, we use the NanoString nCounter® platform. This system directly detects RNA, avoiding the potential for introduced bias with approaches that rely on PCR-based amplification.

We can use NanoString’s immuno-oncology and immunology panels or create a custom panel for your study.

QuantStudio™ 12K flex real-time PCR system

For cost-effective, multiplexed gene expression profiling of many samples in parallel, we offer analyses using OpenArray plates on the QuantStudio 12K Flex qPCR platform.

QX200™ ddPCR™

Digital PCR is appropriate when highly sensitive analyses and absolute quantification is needed. Precision utilizes the Bio-Rad QX200 ddPCR System.

Agena MassARRAY®

High-throughput solution for genotyping, somatic mutation detection, DNA methylation analysis, and gene expression regulation analysis. Precision for Medicine offers MassARRAY® assays either as an individual service or as part of a comprehensive therapeutic development package, which includes biomarker assays and clinical trials.

Precision also provides research-ready biospecimens

In addition to services, Precision has biospecimens ready for genomic analysis, as well as specimens pre-characterized via NGS.

FFPE Tissues Explore NGS Characterized Biospecimens Explore Tissue Microarrays Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Explore our blog
Read: Defaulting to a Big Five CRO? Here’s What Sponsors Wish They Knew First Defaulting to a Big Five CRO? Here’s What Sponsors Wish They Knew First

Defaulting to a Big Five CRO? Here’s What Sponsors Wish They Knew First

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1744830865620, hs_published_at=1744844126301, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=400,height=400,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Rob%20Maiale.jpg',altText='Rob Maiale',fileId=184765575245}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1744843965759, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale
Discover
Read: Key Strategies for Future-Proofing Gene Therapy Assay Validations Key Strategies for Future-Proofing Gene Therapy Assay Validations

Translational Research - Regulatory - Assays - Gene Therapies

Key Strategies for Future-Proofing Gene Therapy Assay Validations

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1744844126301, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716212769184, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=51739740}, second={hs_id=159488778889, hs_child_table_id=0, hs_updated_at=1714461111815, hs_published_at=1744844126301, description=Travis Harrison, PhD, is Vice President of Diagnostic Development at Precision for Medicine. He brings more than 20 years of bioanalytical assay experience to the Precision team with expertise in ligand-binding and cell-based assays.  Travis has experience supporting clinical and nonclinical studies for a broad range of indications, with an emphasis on diagnostic assays to evaluate immune responses to gene therapies., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Travis%20Harrison.webp',altText='Travis Harrison',fileId=165893006481}, linkedin=https://www.linkedin.com/in/travis-harrison-phd-6108852/, hs_name=, hs_path=, lastname=Harrison, hs_initial_published_at=1716212769184, hs_created_at=1709645745120, hs_is_edited=false, hs_deleted_at=0, name=Travis, job=, slug=travis-harrison, email=, hs_updated_by_user_id=51739740}, third={}})
  • Deborah P. avatar

    Deborah P.
  • Travis H. avatar

    Travis H.
Discover
Read: Study Start-Up vs Site Start-Up in Clinical Research: Understanding Modern Trial Dynamics Study Start-Up vs Site Start-Up in Clinical Research: Understanding Modern Trial Dynamics

Clinical Trials

Study Start-Up vs Site Start-Up in Clinical Research: Understanding Modern Trial Dynamics

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=169565849890, hs_child_table_id=0, hs_updated_at=1723217327146, hs_published_at=1744844126301, avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Barbara%20Kathage.jpg',altText='Barbara Kathage',fileId=168426405902}, lastname=Kathage, hs_initial_published_at=1718988967067, hs_created_by_user_id=26433386, hs_created_at=1717603865843, hs_is_edited=false, hs_deleted_at=0, name=Barbara, job=Vice President, Site Start Up, slug=barbara-kathage, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Barbara Kathage avatar

    Barbara Kathage
Discover